In a study, a novel HDAC6 inhibitor (MPT0G612), which induces apoptosis and inhibits IFN-γ-induced programmed death-ligand 1 in human colorectal cancer cells, was found to be a potential strategy for the combination of immune checkpoint inhibitors in the treatment of CRC (34). Here, HDAC6 is linked to colorectal cancer.